JP2022517410A5 - - Google Patents

Info

Publication number
JP2022517410A5
JP2022517410A5 JP2021541206A JP2021541206A JP2022517410A5 JP 2022517410 A5 JP2022517410 A5 JP 2022517410A5 JP 2021541206 A JP2021541206 A JP 2021541206A JP 2021541206 A JP2021541206 A JP 2021541206A JP 2022517410 A5 JP2022517410 A5 JP 2022517410A5
Authority
JP
Japan
Prior art keywords
pyridine
picolinamide
ethoxy
imidazo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021541206A
Other languages
English (en)
Japanese (ja)
Other versions
JP7576552B2 (ja
JP2022517410A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014126 external-priority patent/WO2020150626A1/en
Publication of JP2022517410A publication Critical patent/JP2022517410A/ja
Publication of JP2022517410A5 publication Critical patent/JP2022517410A5/ja
Application granted granted Critical
Publication of JP7576552B2 publication Critical patent/JP7576552B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021541206A 2019-01-18 2020-01-17 イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用 Active JP7576552B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962794098P 2019-01-18 2019-01-18
US62/794,098 2019-01-18
PCT/US2020/014126 WO2020150626A1 (en) 2019-01-18 2020-01-17 Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors

Publications (3)

Publication Number Publication Date
JP2022517410A JP2022517410A (ja) 2022-03-08
JP2022517410A5 true JP2022517410A5 (enExample) 2023-01-27
JP7576552B2 JP7576552B2 (ja) 2024-10-31

Family

ID=69724065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021541206A Active JP7576552B2 (ja) 2019-01-18 2020-01-17 イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用

Country Status (5)

Country Link
US (1) US20220089592A1 (enExample)
EP (1) EP3911652A1 (enExample)
JP (1) JP7576552B2 (enExample)
MA (1) MA54755A (enExample)
WO (1) WO2020150626A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
WO2020259626A1 (zh) * 2019-06-26 2020-12-30 南京明德新药研发有限公司 作为irak4抑制剂的咪唑并吡啶类化合物
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
AR124451A1 (es) 2020-12-22 2023-03-29 Biogen Ma Inc DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES
KR20230134499A (ko) * 2020-12-22 2023-09-21 바이오젠 엠에이 인코포레이티드 Irak4 억제제로서의 2h-인다졸 유도체 및 질환의 치료에서의그의 용도
CN116745294A (zh) * 2020-12-25 2023-09-12 南京明德新药研发有限公司 酰胺噁唑类化合物
CN116867758A (zh) 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
CN112724079A (zh) * 2021-02-04 2021-04-30 康化（上海）新药研发有限公司 一种6-甲氧基吡啶甲酸甲酯的合成方法
US20250018046A1 (en) * 2021-07-07 2025-01-16 Biogen Ma Inc Compounds for targeting degradation of irak4 proteins
TW202330546A (zh) * 2021-12-31 2023-08-01 香港商愛科諾生物醫藥(香港)有限公司 具有irak4抑制活性的化合物，包含其的藥物組合物，及其應用
WO2024020522A1 (en) * 2022-07-22 2024-01-25 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
CN117777126A (zh) * 2022-09-29 2024-03-29 武汉人福创新药物研发中心有限公司 作为irak4降解剂的咪唑并吡啶类化合物及其用途
EP4389747A1 (en) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
WO2024133560A1 (en) * 2022-12-21 2024-06-27 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
CN115959976A (zh) * 2022-12-30 2023-04-14 安徽诺全药业有限公司 一种甲氧基取代双环戊烷衍生物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360620T1 (de) * 2000-08-01 2007-05-15 Sod Conseils Rech Applic Imidazolderivate
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1657242A4 (en) 2003-08-15 2008-10-29 Banyu Pharma Co Ltd imidazopyridine
US20130029967A1 (en) * 2009-09-24 2013-01-31 Centro Nacional De Investigaciones Oncologicas (Cnio) Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors
CN102796103A (zh) * 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
WO2014209841A2 (en) * 2013-06-25 2014-12-31 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
GB201321730D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
LT3466955T (lt) * 2014-01-13 2021-02-25 Aurigene Discovery Technologies Limited Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
BR112016026951B1 (pt) * 2014-06-25 2022-09-20 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pirazin-1-il-benzamida, seu uso, e composições farmacêuticas
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP7576581B2 (ja) * 2019-06-27 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるそれらの使用

Similar Documents

Publication Publication Date Title
JP2022517410A5 (enExample)
JP7576552B2 (ja) イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用
AU2018374456B2 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
JP2023550466A5 (enExample)
KR102758615B1 (ko) 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물
AU2018201903B2 (en) SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
RU2700004C1 (ru) Конденсированные трициклические производные имидазола в качестве модуляторов активности tnf
JP7292271B2 (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
ME02802B (me) P2x7 modulatori
WO2023041049A1 (zh) 作为sos1抑制剂的杂环化合物及其用途
AU2018208766A1 (en) Tank-binding kinase inhibitor compounds
ME02595B (me) Heterociklilamini kao inhibitori pi3k
JP2014527959A5 (enExample)
ME02856B (me) Aminopirimidinilni spojevi kao inhibitori jak
KR20220027196A (ko) 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도
EA037598B1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана
EP4634170A1 (en) Imidazo[4,5-b]pyridine derivatives as pcsk9 inhibitors and methods of use thereof
KR20210057008A (ko) 신규한 헤테로방향족 아미드 유도체 및 이를 함유하는 약제
CA2881638A1 (en) Pyridine derivative and medicine
WO2024015497A1 (en) Tyrosine kinase 2 inhibitors and uses thereof